证券代码：605507 证券简称：国邦医药 公告编号：2025-031 国邦医药集团股份有限公司 关于全资子公司参与设立股权投资基金完成私募投资基金 备案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、对外投资概述 为进一步推动国邦医药集团股份有限公司（以下简称"公司"）的战略及投 资布局，借助专业投资机构和高校科技成果的资源优势，进一步扩大公司在科技 领域投资。公司全资子公司国邦医药（杭州）股权投资有限公司（以下简称"国 邦投资"）与专业投资机构北京砺明创业投资有限公司、浙江大学校友创新创业 有限公司、海联金汇科技股份有限公司、浙江中南建设集团有限公司、广东越科 能源发展有限公司、洪宝民共同签署合伙协议，拟共同投资设立杭州启真开物股 权投资基金合伙企业（有限合伙）（以下简称"合伙企业"），重点投资符合国 家战略性新兴产业、未来产业发展方向领域的公司。 合伙企业认缴出资额为人民币 5,000 万元，其中国邦投资作为有限合伙人以 自有资金认缴出资人民币 1,000 万元，认缴出资占比为 20%。具体内容详见公司 于 ...

证券代码：605507 证券简称：国邦医药 公告编号：2025-030 国邦医药集团股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至 2025 年 6 月 30 日，公司通过集中竞价交易方式累计回购股份 5,375,274 股，已回购股份占公司总股本的比例为 0.96%，成交的最高价为 19.88 元/股，最低 价为 18.61 元/股，已支付的总金额为 102,600,172.21 元（不含交易费用）。 上述回购事项符合相关法律法规的规定及公司回购股份方案的要求。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律 监管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做 出回购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务， 敬请广大投资者注意投资风险。 特此公告。 | 回购方案首次披露日 | 2025/3/11 | | --- | --- | | 回购方案实施期限 | 2025/3/11~2026/3 ...

Investment Rating - The report maintains a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Bioscience, Hualing Pharmaceutical-B, and others [2]. Core Insights - The report emphasizes the broad market for lipid-lowering treatments, particularly focusing on the competitive landscape of PCSK9-targeted drugs, with approximately 500 million adults in China suffering from dyslipidemia, including 120 million with high cholesterol [3][15]. - The pharmaceutical sector saw a 1.60% increase this week, underperforming the CSI 300 index by 0.35 percentage points, with sub-sectors like medical infrastructure and life sciences performing better than generics and innovative drugs [4][31]. Summary by Sections 1. Industry Perspective and Investment Recommendations - The lipid-lowering market is vast, with intense competition in PCSK9-targeted drugs [15]. - Investment strategies should focus on innovative drugs, particularly in the context of increased liquidity and risk appetite in the market [4][31]. 2. Pharmaceutical Sector Performance - The pharmaceutical sector's performance was mixed, with medical infrastructure and life sciences leading, while generics and innovative drugs lagged [4][37]. - The overall P/E ratio for the pharmaceutical industry is 27.69, with a premium of 35.26% compared to the broader A-share market [37]. 3. Company Dynamics - Notable company announcements include Baiyoutai's licensing agreement for BAT2406 in Latin America and Yifan Pharmaceutical's approval for clinical trials of a growth hormone injection [38][40]. - Companies like WuXi AppTec and Lijun Group have made significant moves, including share buybacks and new product approvals [39][41]. 4. Industry Trends - The report highlights the upcoming patent expirations for major small molecule drugs, which could lead to increased demand for raw materials [5][32]. - The report also notes the expected recovery in overseas demand, which may improve the performance of CXO companies [34]. 5. Research and Development Focus - The report discusses the clinical progress of various PCSK9-targeted therapies, including monoclonal antibodies and gene editing approaches, indicating a strong pipeline in this area [3][23][25]. - The competitive landscape for PCSK9 drugs in China is characterized by pricing and adherence challenges, with several products already on the market [27].

Group 1 - Beixin Road and Bridge's application for issuing shares to specific targets has been approved by the Shenzhen Stock Exchange, pending approval from the China Securities Regulatory Commission [1] - Wangbian Electric's shareholders plan to reduce their holdings by a total of up to 2.99% of the company's shares, with specific reductions detailed for each shareholder [1] - Guotou Zhonglu is planning a major asset restructuring, leading to a suspension of its stock trading for up to 10 trading days [2] Group 2 - Baiotai has signed a licensing agreement with SteinCares for the commercialization of BAT2406 in Brazil and Latin America, with total payments potentially reaching up to $10 million [3] - Dongfang Bio has obtained two medical device registration certificates for its products, which are valid until June 1, 2030 [4] - Pulaike's subsidiary has received a new veterinary drug registration certificate [5] Group 3 - Wanyi Technology has signed an agreement to establish a joint laboratory with the Energy Research Institute, with a total research and development budget of 6 million yuan [6] - Yingboer plans to use up to 300 million yuan of idle funds for financial management [7] - Blue Biological has received two new veterinary drug registration certificates [8] Group 4 - Jinkai New Energy intends to inject up to 1.247 billion yuan into its wholly-owned subsidiary to enhance its operational capabilities [9] - China Pacific Insurance's assistant general manager's qualification has been approved [10] - Zhaoyan New Drug is reducing its registered capital and notifying creditors [11] Group 5 - Weili Medical plans to invest 37.5 million yuan in establishing a medical industry investment fund [12] - Hongbai New Materials has signed a deposit agreement for idle raised funds [13] - Tongyou Technology is applying for a credit limit of 10 million yuan from a bank [14] Group 6 - Warner Pharmaceutical's subsidiary has received approval for its magnesium sulfate raw material drug [15] - Fuda Co. plans to establish a wholly-owned subsidiary with a capital contribution of 475 million yuan [16] - Yabao Pharmaceutical has obtained a loan commitment letter for stock repurchase of up to 90 million yuan [17] Group 7 - Zhongyin Securities' chairman has resigned due to work adjustments [18] - Aili Home has terminated its share reduction plan ahead of schedule [19] - Samsung New Materials has appointed a new financial officer [20] Group 8 - Guobang Pharmaceutical's subsidiary has received EU GMP certification for its product [21] - Yipin Hong has received a drug registration certificate for its injection solution [22] - Wenzhou Hongfeng's subsidiary has obtained a utility model patent certificate [23] Group 9 - Cangge Mining plans to sign a financial service agreement with Zijin Mining Group [24] - Naipu Mining's application for convertible bonds has been accepted by the Shenzhen Stock Exchange [25] - Shenyang Machine Tool has completed its major asset restructuring [26] Group 10 - Xinlaifu plans to distribute a cash dividend of 5 yuan per 10 shares [27] - Jiashitang plans to distribute a cash dividend of 1.7 yuan per 10 shares [28] - Manbuer plans to distribute a cash dividend of 2.5 yuan per 10 shares [29] Group 11 - Guo Wang Yingda plans to distribute a cash dividend of 0.51 yuan per 10 shares [30] - Changsha Bank's shareholder plans to reduce holdings by up to 0.92% [31] - Hu Nong Commercial Bank plans to distribute a cash dividend of 1.93 yuan per 10 shares [32] Group 12 - Huaxiang Co. plans to distribute a cash dividend of 1.17 yuan per 10 shares [33]

证券代码：605507 证券简称：国邦医药 公告编号：2025-029 国邦医药集团股份有限公司 关于全资子公司产品泰拉霉素通过欧盟 GMP 认证 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 国邦医药集团股份有限公司董事会 2025 年 6 月 24 日 一、GMP 证书相关信息 （一）企业名称：浙江国邦药业有限公司 二、对公司的影响及风险提示 公司近年来持续加强特色原料药业务发展，产品布局 30 余个，不断推动特 色原料药出口相关工作。根据欧盟成员国之间的 GMP 互认制度，通过 GMP 认 证表明本次接受认证的生产线已符合欧盟 GMP 标准。本次泰拉霉素通过欧盟 GMP 认证，有利于公司进一步推进海外市场的拓展，提高公司的市场竞争力， 未来将对公司经营产生积极影响。 由于原料药产品的行业特点，国际原料药业务易受海外市场环境变化、行业 政策、供求关系等因素影响，具有一定的不确定性。敬请广大投资者理性投资， 注意投资风险。 （二）生产地址：浙江省绍兴市上虞区杭州湾经济技术开发区纬五路 6 号 （三）证书编号：DE_ ...

Core Viewpoint - The company has received GMP certification for its raw material, Tylosin, from the German Hamburg Ministry of Health and Consumer Protection, which will enhance its competitiveness in the overseas market and positively impact its operations [1] Group 1 - The company's wholly-owned subsidiary, Zhejiang Guobang Pharmaceutical Co., Ltd., is the entity that received the GMP certification [1] - The EU GMP certification is expected to facilitate the company's expansion into international markets [1] - The certification is anticipated to improve the company's market competitiveness [1]

证券代码：605507 证券简称：国邦医药 公告编号：2025-028 三、其他情况说明 公司将按照《上海证券交易所股票上市规则》及相关法律法规的要求，密切 关注投资基金的后续进展情况，及时履行信息披露义务，敬请广大投资者注意投 资风险。 特此公告。 国邦医药集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、对外投资概述 为进一步推动国邦医药集团股份有限公司（以下简称"公司"）的战略及投 资布局，借助专业投资机构和高校科技成果的资源优势，进一步扩大公司在科技 领域投资。公司全资子公司国邦医药（杭州）股权投资有限公司（以下简称"国 邦投资"）作为有限合伙人以自有资金 1,000 万元人民币参与设立股权投资基金， 重点投资符合国家战略性新兴产业、未来产业发展方向领域的公司。具体内容详 见公司于 2025 年 4 月 22 日在上海证券交易所网站（www.sse.com.cn）披露的《国 邦医药关于全资子公司参与设立股权投资基金的公告》（公告编号：2025-021）。 二、对外投资进展 近日，公司收到杭州启真开物 ...

Investment Rating - The report recommends a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Biosciences, Hualing Pharmaceutical-B, and others [3]. Core Insights - The pharmaceutical sector has outperformed the market, with a focus on the potential of innovative drugs and the CD73 target in cancer immunotherapy [4][5]. - The report highlights the promising clinical progress of CD73 inhibitors, with several products in various stages of clinical trials [21][25]. Summary by Sections Industry Investment Rating - The report provides a list of recommended companies with "Buy" and "Hold" ratings, indicating strong investment potential in the pharmaceutical sector [3]. Industry Performance - The pharmaceutical sector rose by 1.13%, outperforming the CSI 300 index by 0.25 percentage points, with innovative drugs and vaccines leading the performance [5][32]. Company Dynamics - Companies such as Lepu Medical and Sunshine Nuohua have made significant announcements regarding new product approvals and clinical trial progress, indicating a robust pipeline and growth potential [33][34]. Industry Trends - The report discusses the increasing focus on innovative drugs and the impact of regulatory changes on the pharmaceutical landscape, suggesting a shift towards high-efficiency business models in the industry [31][40].

国浩律师（杭州）事务所 关 于 国邦医药集团股份有限公司 差异化分红事项 之 专项法律意见书 关 于 地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号国浩律师楼 邮编：310008 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejiang 310008, China 电话/Tel: (+86)(571) 8577 5888 传真/Fax: (+86)(571) 8577 5643 电子邮箱/Mail：grandallhz@grandall.com.cn 网址/Website：http://www.grandall.com.cn 二〇二五年五月 国浩律师（杭州）事务所 法律意见书 国浩律师（杭州）事务所 国邦医药集团股份有限公司 差异化分红事项 之 专项法律意见书 致：国邦医药集团股份有限公司 国浩律师（杭州）事务所接受国邦医药集团股份有限公司（以下简称"国邦 医药"或"公司"）的委托，根据《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》（以下简称"《证 ...

每股分配比例 A 股每股现金红利0.60583元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/12 | － | 2025/6/13 | 2025/6/13 | 差异化分红送转： 是 一、通过分配方案的股东大会届次和日期 证券代码：605507 证券简称：国邦医药 公告编号：2025-027 国邦医药集团股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次利润分配方案经公司2025 年 4 月 25 日的2024年年度股东大会审议通过。 二、分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 根据《上海证券交易所上市公司自律监管指引第 7 号—回购股份》的规定， 公司存放于回购 ...